Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.57 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.56 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.56 |
| ▸ | REN | P00797 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430579 | 0.87 | NMUR2 (0.62) | NMUR2NMUR1 | |
| SCHEMBL29531913 | 0.87 | OPRM1 (0.56) | NMUR2OPRM1OPRD1OPRK1NMUR1 | |
| SCHEMBL29588428 | 0.87 | SLC6A2 (0.55) | NMUR2OPRM1OPRD1NMUR1CALCRL | |
| SCHEMBL11443805 | 0.87 | SLC6A2 (0.68) | NMUR2OPRM1OPRD1NMUR1REN | |
| SCHEMBL30753165 | 0.86 | BACE1 (0.54) | NMUR2OPRM1OPRD1OPRK1NMUR1 | |
| SCHEMBL29580824 | 0.86 | POLB (0.56) | OPRM1OPRD1OPRK1 | |
| SCHEMBL30444297 | 0.86 | CALCRL (0.61) | NMUR2OPRM1OPRD1OPRK1CALCRL | |
| SCHEMBL31694455 | 0.86 | SLC6A2 (0.58) | OPRM1OPRD1OPRK1REN | |
| SCHEMBL28915426 | 0.86 | NMUR2 (0.58) | NMUR2OPRM1OPRD1OPRK1NMUR1 | |
| SCHEMBL28915423 | 0.86 | NMUR2 (0.58) | NMUR2OPRM1OPRD1OPRK1NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544431-B2 | Peptides for the treatment of cancer and/or metastasis | BCN PEPTIDES, S.A. (ES) | 2026-02-10 | — | — | US | disclosed |
| US-20240238390-A1 | PEPTIDES FOR THE TREATMENT OF CANCER AND/OR METASTASIS | BCN PEPTIDES, S.A. (ES) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238390-A1 | PEPTIDES FOR THE TREATMENT OF CANCER AND/OR METASTASIS | ADAM12, ADAM17, ADAM9 | NMUR2 1093/4885OPRM1 2641/4885OPRD1 4019/4885 |
| US-12544431-B2 | Peptides for the treatment of cancer and/or metastasis | ADAM12, PTMS, LNPEP | NMUR2 1950/4885OPRM1 185/4885OPRD1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.